Lucira Health, Inc.

LHDXDelisted Apr 12, 2023

Industry: In Vitro & In Vivo Diagnostic Substances
SEC CIK: 0001652724

SEC filings (opens in a new tab)

Lucira Health, Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Mar 13, 2023; 29 institutions reported holding it in 13F filings for Q4 2022, worth $1.04M in total; no superinvestor held it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 29; Q4 2022, +1 vs. previous quarter
13F value: $1.04M; Reported value at the end of Q4 2022
Superinvestors holding: 0; At the end of Q4 2022

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2021: $93.1M; No comparable prior period
Net income, FY2021: -$64.8M; No comparable prior period
Free cash flow, FY2021: -$116.3M; No comparable prior period
Revenue, Q3 FY2022: $34.4M; +130.9% year over year

Superinvestors holding LHDX, Q4 2022

Go to the superinvestors tab

No superinvestor reported holding LHDX at the end of Q4 2022.

Latest insider trades

See all insider trades

Open-market purchases and sales by Lucira Health, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Mar 13, 2023 (view filing)5:10 PM ET	Mar 3-7	10 daysLate	Narido Richard ClavanoChief Financial Officer	SSale	−29.4K	$1.00	−$29.4K	−27.4%77.9K after	5 lots
Mar 13, 2023 (view filing)5:09 PM ET	Mar 3-7	10 daysLate	Collins Kevin WalterChief Revenue Officer	SSale	−111.8K	$0.6604	−$73.8K	−32.3%234.9K after	2 lots
Mar 13, 2023 (view filing)	Mar 3	10 daysLate	Engelson Erik T.President and Chief Executive	SSale	−634.7K	$1.04	−$657.3K	−96.5%23.3K after	2 lots
Mar 13, 2023 (view filing)	Mar 3	10 daysLate	Allen Anthony JosephChief Operations Officer	SSale	−8.40K	$1.00	−$8.40K	−5.8%136.5K after
Feb 21, 2023 (view filing)12:38 PM ET	Feb 16	5 days	Kashmolah GhaziEx VP & Chief Quality Officer	SSale	−5.03K	$0.27	−$1.36K	−3.6%134.1K after
Dec 22, 2022 (view filing)2:24 PM ET	Dec 20	2 days	Allen Anthony JosephChief Operations Officer	SSale	−4.26K	$0.16	−$682.08	−2.9%144.9K after
Dec 9, 2022 (view filing)4:24 PM ET	Nov 21	18 daysLate	Allen Anthony JosephChief Operations Officer	SSale	−34.4K	$0.33	−$11.4K	−18.8%149.2K after	2 lots
Dec 9, 2022 (view filing)4:17 PM ET	Nov 28	11 daysLate	Kashmolah GhaziEx VP & Chief Quality Officer	SSale	−7.54K	$0.42	−$3.17K	−5.1%139.1K after
Dec 9, 2022 (view filing)4:15 PM ET	Nov 17	22 daysLate	Kashmolah GhaziEx VP & Chief Quality Officer	SSale	−33.2K	$0.3724	−$12.4K	−18.5%146.6K after	2 lots
Dec 6, 2022 (view filing)4:21 PM ET	Dec 1	5 daysLate	Narido Richard ClavanoInterim CFO	SSale	−1.58K	$0.36	−$569.88	−1.5%107.3K after

Top 10 13F holders, Q4 2022

See all 29 holders

The largest institutional positions in Lucira Health, Inc. at the end of Q4 2022; share changes are against Q3 2022.

Institutions holding LHDX in Q4 2022
Institution	Shares	Value	% of portfolio	Change in shares	Action
Eclipse Ventures, LLC	6,223,795	$690.8K	0.62%	00.0%	Unchanged
EPIQ Capital Group, LLC	725,675	$80.5K	0.05%	−13,011,695−94.7%	Reduced
Vanguard Group Inc	623,488	$69.3K	0.00%	−8,279−1.3%	Reduced
Citigroup Inc	436,840	$48.5K	0.00%	−181,803−29.4%	Reduced
Balyasny Asset Management LLC	271,030	$30.1K	0.00%	−55,168−16.9%	Reduced
Morgan Stanley	207,755	$23.1K	0.00%	−4,399−2.1%	Reduced
Papp L Roy & Associates	150,699	$16.7K	0.00%	+36,205+31.6%	Added
Bridgeway Capital Management, LLC	110,500	$12.3K	0.00%	−14,200−11.4%	Reduced
Consilio Wealth Advisors, LLC	90,199	$10.0K	0.01%	−7,319−7.5%	Reduced
Geode Capital Management, LLC	95,621	$10.0K	0.00%	00.0%	Unchanged